Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Immunocore’s Lead Asset Tebentafusp Gains Fast Track Designation for Metastatic Uveal Melanoma

drugsApril 17, 2019

Tag: Immunocore , tebentafusp , melanoma , IMCgp , metastatic

PharmaSources Customer Service